IFM Investors Pty Ltd Increases Position in Eli Lilly and Company (NYSE:LLY)

IFM Investors Pty Ltd increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,316 shares of the company's stock after purchasing an additional 13,800 shares during the quarter. Eli Lilly and Company makes up approximately 1.5% of IFM Investors Pty Ltd's holdings, making the stock its 10th largest holding. IFM Investors Pty Ltd's holdings in Eli Lilly and Company were worth $148,232,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of LLY. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $43,000. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $48,000. Finally, O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.0%

Shares of NYSE LLY opened at $779.60 on Friday. The stock has a market cap of $738.85 billion, a P/E ratio of 63.43, a PEG ratio of 1.14 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The business's fifty day simple moving average is $773.61 and its 200-day simple moving average is $799.72.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.58 earnings per share. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. UBS Group lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Guggenheim restated a "buy" rating and issued a $936.00 price target on shares of Eli Lilly and Company in a research report on Friday, June 20th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.